Alternaria alternata immunotherapy

Drug Profile

Alternaria alternata immunotherapy

Alternative Names: A. alternata immunotherapy

Latest Information Update: 11 Mar 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bial
  • Developer BIAL
  • Class Fungal allergy immunotherapies; Mould allergy immunotherapies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Clinical Phase Unknown Allergic asthma; Allergic rhinitis

Most Recent Events

  • 10 Mar 2008 Clinical trials in Allergic asthma in Spain (SC)
  • 10 Mar 2008 Investigation in Allergic rhinitis in Spain (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top